A placebo-controlled double blind preliminary trial to study the efficacy and safety of Gelclair in controlling the symptoms of oral lichen planus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN60732049

Enrollment

Registered

2004-09-30

Start date

2004-01-15

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases: Oral lichen planus Skin and Connective Tissue Diseases Oral lichen planus

Interventions

Patients presenting to the department of oral medicine will be assessed for their suitability for inclusion within the trial. They will be invited to take part if they are diagnosed with lichen planus

Eligibility

Inclusion criteria

Inclusion criteria: 30 patients in control (placebo) group, 30 in Gelclair. Matched by symptoms and extent of disease at initial presentation.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Gelclair is of use in managing the symptoms of pain in oral lichen planus. Primary response criteria: symptom control over an eight-week period, usage of topical corticosteroids (patient-controlled).	—

Secondary

Measure	Time frame
Tolerability and acceptability	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026